Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $3,489,673.32 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 315,522 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the sale, the chief operating officer now directly owns 959,457 shares of the company’s stock, valued at approximately $10,611,594.42. The trade was a 24.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.

Roivant Sciences Trading Up 0.4 %

NASDAQ ROIV traded up $0.04 on Monday, hitting $10.83. 6,976,198 shares of the company’s stock traded hands, compared to its average volume of 5,636,264. The firm’s 50-day moving average price is $10.78 and its two-hundred day moving average price is $11.46. The firm has a market capitalization of $7.73 billion, a PE ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a 1-year low of $9.93 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, research analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in Roivant Sciences in the 4th quarter worth approximately $39,000. GAMMA Investing LLC boosted its position in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Quarry LP lifted its stake in shares of Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after purchasing an additional 2,500 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.